Cargando…

Vaginal Lactoferrin Modulates PGE(2), MMP-9, MMP-2, and TIMP-1 Amniotic Fluid Concentrations

Inflammation plays an important role in pregnancy, and cytokine and matrix metalloproteases (MMPs) imbalance has been associated with premature rupture of membranes and increased risk of preterm delivery. Previous studies have demonstrated that lactoferrin (LF), an iron-binding protein with anti-inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Trentini, Alessandro, Maritati, Martina, Cervellati, Carlo, Manfrinato, Maria C., Gonelli, Arianna, Volta, Carlo A., Vesce, Fortunato, Greco, Pantaleo, Dallocchio, Franco, Bellini, Tiziana, Contini, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107848/
https://www.ncbi.nlm.nih.gov/pubmed/27872513
http://dx.doi.org/10.1155/2016/3648719
_version_ 1782467262916067328
author Trentini, Alessandro
Maritati, Martina
Cervellati, Carlo
Manfrinato, Maria C.
Gonelli, Arianna
Volta, Carlo A.
Vesce, Fortunato
Greco, Pantaleo
Dallocchio, Franco
Bellini, Tiziana
Contini, Carlo
author_facet Trentini, Alessandro
Maritati, Martina
Cervellati, Carlo
Manfrinato, Maria C.
Gonelli, Arianna
Volta, Carlo A.
Vesce, Fortunato
Greco, Pantaleo
Dallocchio, Franco
Bellini, Tiziana
Contini, Carlo
author_sort Trentini, Alessandro
collection PubMed
description Inflammation plays an important role in pregnancy, and cytokine and matrix metalloproteases (MMPs) imbalance has been associated with premature rupture of membranes and increased risk of preterm delivery. Previous studies have demonstrated that lactoferrin (LF), an iron-binding protein with anti-inflammatory properties, is able to decrease amniotic fluid (AF) levels of IL-6. Therefore, we aimed to evaluate the effect of vaginal LF administration on amniotic fluid PGE(2) level and MMP-TIMP system in women undergoing genetic amniocentesis. One hundred and eleven women were randomly divided into controls (n = 57) or treated with LF 4 hours before amniocentesis (n = 54). Amniotic fluid PGE(2), active MMP-9 and MMP-2, and TIMP-1 and TIMP-2 concentrations were determined by commercially available assays and the values were normalized by AF creatinine concentration. PGE(2), active MMP-9, and its inhibitor TIMP-1 were lower in LF-treated group than in controls (p < 0.01, p < 0.005, and p < 0.001, resp.). Conversely, active MMP-2 (p < 0.0001) and MMP-2/TIMP-2 molar ratio (p < 0.001) were increased, whilst TIMP-2 was unchanged. Our data suggest that LF administration is able to modulate the inflammatory response following amniocentesis, which may counteract cytokine and prostanoid imbalance that leads to abortion. This trial is registered with Clinical Trial number NCT02695563.
format Online
Article
Text
id pubmed-5107848
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-51078482016-11-21 Vaginal Lactoferrin Modulates PGE(2), MMP-9, MMP-2, and TIMP-1 Amniotic Fluid Concentrations Trentini, Alessandro Maritati, Martina Cervellati, Carlo Manfrinato, Maria C. Gonelli, Arianna Volta, Carlo A. Vesce, Fortunato Greco, Pantaleo Dallocchio, Franco Bellini, Tiziana Contini, Carlo Mediators Inflamm Clinical Study Inflammation plays an important role in pregnancy, and cytokine and matrix metalloproteases (MMPs) imbalance has been associated with premature rupture of membranes and increased risk of preterm delivery. Previous studies have demonstrated that lactoferrin (LF), an iron-binding protein with anti-inflammatory properties, is able to decrease amniotic fluid (AF) levels of IL-6. Therefore, we aimed to evaluate the effect of vaginal LF administration on amniotic fluid PGE(2) level and MMP-TIMP system in women undergoing genetic amniocentesis. One hundred and eleven women were randomly divided into controls (n = 57) or treated with LF 4 hours before amniocentesis (n = 54). Amniotic fluid PGE(2), active MMP-9 and MMP-2, and TIMP-1 and TIMP-2 concentrations were determined by commercially available assays and the values were normalized by AF creatinine concentration. PGE(2), active MMP-9, and its inhibitor TIMP-1 were lower in LF-treated group than in controls (p < 0.01, p < 0.005, and p < 0.001, resp.). Conversely, active MMP-2 (p < 0.0001) and MMP-2/TIMP-2 molar ratio (p < 0.001) were increased, whilst TIMP-2 was unchanged. Our data suggest that LF administration is able to modulate the inflammatory response following amniocentesis, which may counteract cytokine and prostanoid imbalance that leads to abortion. This trial is registered with Clinical Trial number NCT02695563. Hindawi Publishing Corporation 2016 2016-10-31 /pmc/articles/PMC5107848/ /pubmed/27872513 http://dx.doi.org/10.1155/2016/3648719 Text en Copyright © 2016 Alessandro Trentini et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Trentini, Alessandro
Maritati, Martina
Cervellati, Carlo
Manfrinato, Maria C.
Gonelli, Arianna
Volta, Carlo A.
Vesce, Fortunato
Greco, Pantaleo
Dallocchio, Franco
Bellini, Tiziana
Contini, Carlo
Vaginal Lactoferrin Modulates PGE(2), MMP-9, MMP-2, and TIMP-1 Amniotic Fluid Concentrations
title Vaginal Lactoferrin Modulates PGE(2), MMP-9, MMP-2, and TIMP-1 Amniotic Fluid Concentrations
title_full Vaginal Lactoferrin Modulates PGE(2), MMP-9, MMP-2, and TIMP-1 Amniotic Fluid Concentrations
title_fullStr Vaginal Lactoferrin Modulates PGE(2), MMP-9, MMP-2, and TIMP-1 Amniotic Fluid Concentrations
title_full_unstemmed Vaginal Lactoferrin Modulates PGE(2), MMP-9, MMP-2, and TIMP-1 Amniotic Fluid Concentrations
title_short Vaginal Lactoferrin Modulates PGE(2), MMP-9, MMP-2, and TIMP-1 Amniotic Fluid Concentrations
title_sort vaginal lactoferrin modulates pge(2), mmp-9, mmp-2, and timp-1 amniotic fluid concentrations
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107848/
https://www.ncbi.nlm.nih.gov/pubmed/27872513
http://dx.doi.org/10.1155/2016/3648719
work_keys_str_mv AT trentinialessandro vaginallactoferrinmodulatespge2mmp9mmp2andtimp1amnioticfluidconcentrations
AT maritatimartina vaginallactoferrinmodulatespge2mmp9mmp2andtimp1amnioticfluidconcentrations
AT cervellaticarlo vaginallactoferrinmodulatespge2mmp9mmp2andtimp1amnioticfluidconcentrations
AT manfrinatomariac vaginallactoferrinmodulatespge2mmp9mmp2andtimp1amnioticfluidconcentrations
AT gonelliarianna vaginallactoferrinmodulatespge2mmp9mmp2andtimp1amnioticfluidconcentrations
AT voltacarloa vaginallactoferrinmodulatespge2mmp9mmp2andtimp1amnioticfluidconcentrations
AT vescefortunato vaginallactoferrinmodulatespge2mmp9mmp2andtimp1amnioticfluidconcentrations
AT grecopantaleo vaginallactoferrinmodulatespge2mmp9mmp2andtimp1amnioticfluidconcentrations
AT dallocchiofranco vaginallactoferrinmodulatespge2mmp9mmp2andtimp1amnioticfluidconcentrations
AT bellinitiziana vaginallactoferrinmodulatespge2mmp9mmp2andtimp1amnioticfluidconcentrations
AT continicarlo vaginallactoferrinmodulatespge2mmp9mmp2andtimp1amnioticfluidconcentrations